11.28.22 -- Jump-Start Your Next CDMO Outsourcing Project With This Checklist

With higher cell densities and titers come higher contaminant levels, as well as more cluttered debris fields that must be purified to obtain the manufacturer’s product of interest.

Follow the feasibility of xeno‑free NK cell expansion, closure of key unit operations, and how future work could focus on finetuning each step to generate a robust, scalable process.

A new manufacturing platform offers significant benefits for clinical production of lentiviral vectors and further enables support for the continuing global demand for high-quality gene and cell therapy products.

Using cloning and expression technologies and running workstream activities in parallel through an integrated services approach enables reduced timelines without increased development risks.

Learn how utilizing high-density cell banking workflows in combination with your already intensified upstream process can further enhance your process productivity while reducing contamination risks.

Single-use strategies and tools are constantly evolving to better serve industry needs, and adept solutions providers can help streamline development with simple, custom adaptations.

There are a range of benefits to using an integrated supplier to streamline biologic drug development starting in early phases through clinical and commercial stages.

Using key attributes to monitor development processes can decrease timelines, improve product quality, reduce cost, and enable implementation of key knowledge gained from an analytical toolkit.

Cell and gene therapies (CGT) are bringing new hope to patients experiencing rare and serious diseases. And they are disrupting the biopharma market in new and challenging ways.

How a client preparing for the U.S. launch of a CAR T-cell therapy leveraged assistance assessing the current landscape and gathering relevant input for access and distribution strategy development.

Before you sign on the dotted line, do a little digging to unearth potential costs that could turn your development program into a cash-burning exercise.

Regenerative medicine company ViaCyte Inc. explored new technologies to enable expanded scales of culturing hESCs for development of cell replacement therapies as a functional cure for Type 1 diabetes.

Explore why virus-like particles have gained continuous interest and why the absence of viral genomic material enhances the safety of VLP-based vaccines. 

We demonstrate how processes can be successfully transferred across different systems without impacting the process performance or product quality.

Learn about an alternative to the traditional method for seed train expansion that can jumpstart manufacturing by several weeks, removing a large part of the seed train from the critical path to production.